Nova Biomedical $2.2 billion acquisition by Advanced Instruments
We are advising Nova Biomedical on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
Endo divestiture of International Pharmaceuticals business
We are advising Endo on the transaction
Sycamore Partners up to $23.7 billion acquisition of Walgreens Boots Alliance
We are advising Sycamore Partners on the transaction
McKesson $850 million acquisition of controlling interest in PRISM Vision
We are advising McKesson on the transaction
Maze Therapeutics $140 million IPO
The shares are listed on Nasdaq
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition